RNActive^®-derived molecules are based on messenger RNA (mRNA), a nucleic acid molecule related to DNA that is found in all forms of life. However, while DNA comprises two nucleotide strands forming the twisted double helix, RNA is usually a single-stranded molecule. Therefore RNA is a rather unstable biomolecule and is rapidly digested in the human body. As a result, its potential role as a therapeutic was overlooked for decades - despite its central role to physically transfer genetic information from the nucleus to the cellular protein production machinery, which then translates the mRNA-encoded information into proteins. CureVac has demonstrated it is possible to modify mRNA making it suitable for therapeutic purposes while maintaining its physiological properties.

An adjuvant is a substance that helps and enhances the pharmacological effect of a drug or increases the ability of an antigen to stimulate the immune system.

• HOME
• ABOUT CUREVAC

• CureVac technologies
• Production

CureVac technologies

RNAs are essential, primordial biomolecules found in nature, a group of molecules that consists of many specialized members with different functions. mRNA has the ability to transmit genetic information, a key process in the development and evolution of living organisms and, thus, is one of the most important molecules for all forms of life. By utilizing its unique properties and overcoming its limitations such as instability, CureVac transforms mRNA into an entirely new class of therapeutic molecule with wide-ranging potential applications.

 

RNActive®

CureVac is combining both the antigenic and adjuvant properties of mRNAs to develop novel and effective mRNA vaccines. CureVac is currently developing therapeutic mRNA vaccines in oncology and therapeutic/prophylactic vaccines for infectious diseases.

RNAdjuvant®

CureVac’s RNAdjuvant® are modified, non-coding, long and complexed RNA molecules to increase the efficacy of a large number of different vaccines, including protein- and peptide-based vaccines without toxic effects.

Production

CureVac’s in-house GMP facility allows for the simultaneous production of several RNA products in parallel. The production pace can easily be altered to meet market demands.

CureVac holds numerous patents and patent applications covering multiple aspects of its RNActive® and RNAdjuvant® technologies.